Synthesis and biological characterisation of 18F-SIG343 and 18F-SIG353, novel and high selectivity σ2 radiotracers, for tumour imaging properties

[1]  Zong-Wen Wu,et al.  Sigma‐2 Receptor Ligands and Their Perspectives in Cancer Diagnosis and Therapy , 2014, Medicinal research reviews.

[2]  R. Craven,et al.  S2RPgrmc1: the cytochrome-related sigma-2 receptor that regulates lipid and drug metabolism and hormone signaling , 2012, Expert opinion on drug metabolism & toxicology.

[3]  A. Hajipour,et al.  Electron-donating para-methoxy converts a benzamide-isoquinoline derivative into a highly Sigma-2 receptor selective ligand. , 2011, Bioorganic & medicinal chemistry.

[4]  M. Grégoire,et al.  Comparison of Cannabinoid CB1 Receptor Binding in Adolescent and Adult Rats: A Positron Emission Tomography Study Using [18F]MK-9470 , 2011, International journal of molecular imaging.

[5]  R. Hotchkiss,et al.  Identification of the PGRMC1 protein complex as the putative sigma-2 receptor binding site , 2011, Nature communications.

[6]  R. Mach,et al.  Radiosynthesis and biological evaluation of a promising sigma(2)-receptor ligand radiolabeled with fluorine-18 or iodine-125 as a PET/SPECT probe for imaging breast cancer. , 2010, Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine.

[7]  K. Ishiwata,et al.  Sigma receptors in oncology: therapeutic and diagnostic applications of sigma ligands. , 2010, Current pharmaceutical design.

[8]  Teruo Hayashi,et al.  Sigma-1 receptor chaperones and diseases. , 2009, Central nervous system agents in medicinal chemistry.

[9]  R. Mach,et al.  New N-substituted 9-azabicyclo[3.3.1]nonan-3alpha-yl phenylcarbamate analogs as sigma2 receptor ligands: synthesis, in vitro characterization, and evaluation as PET imaging and chemosensitization agents. , 2009, Bioorganic & medicinal chemistry.

[10]  Martin Gotthardt,et al.  Spatial Resolution and Sensitivity of the Inveon Small-Animal PET Scanner , 2008, Journal of Nuclear Medicine.

[11]  Teruo Hayashi,et al.  Sigma-1 Receptor Chaperones at the ER- Mitochondrion Interface Regulate Ca2+ Signaling and Cell Survival , 2007, Cell.

[12]  R. Mach,et al.  Fluorine-18-labeled benzamide analogues for imaging the sigma2 receptor status of solid tumors with positron emission tomography. , 2007, Journal of medicinal chemistry.

[13]  E. Aydar,et al.  The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines. , 2006, Cancer letters.

[14]  R. Mach,et al.  Synthesis and In Vivo Evaluation of 2 High-Affinity 76Br-Labeled σ2-Receptor Ligands , 2006 .

[15]  J. Stachnik,et al.  Inhaled anesthetic agents. , 2006, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[16]  R. Mach,et al.  Characterization of a novel iodinated sigma-2 receptor ligand as a cell proliferation marker. , 2006, Nuclear medicine and biology.

[17]  R. Mach,et al.  Carbon-11 labeled σ2 receptor ligands for imaging breast cancer , 2005 .

[18]  R. Craven,et al.  Overexpression of the Cytochrome P450 Activator Hpr6 (Heme-1 Domain Protein/Human Progesterone Receptor) in Tumors , 2005, Tumor Biology.

[19]  Keiichi Oda,et al.  Tumor Imaging with 2 -Receptor Ligands, 18 F- FE-SA5845 and 11 C-SA4503: A Feasibility Study , 2004 .

[20]  J. Cedarbaum.  Survival , 2004 .

[21]  P. Sokoloff,et al.  Development of Novel 1,2,3,4‐Tetrahydroisoquinoline Derivatives and Closely Related Compounds as Potent and Selective Dopamine D3 Receptor Ligands , 2004, Chembiochem : a European journal of chemical biology.

[22]  R. Mach,et al.  Conformationally-flexible benzamide analogues as dopamine D3 and σ2 receptor ligands , 2004 .

[23]  R. Waterhouse,et al.  Determination of lipophilicity and its use as a predictor of blood-brain barrier penetration of molecular imaging agents. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[24]  M. Pacyna‐Gengelbach,et al.  Gene expression profiles in human non-small and small-cell lung cancers. , 2003, European journal of cancer.

[25]  G. Pasternak,et al.  Molecular cloning and pharmacological characterization of the rat sigma1 receptor. , 2001, Biochemical pharmacology.

[26]  D. Wong,et al.  Column-switching HPLC for the analysis of plasma in PET imaging studies. , 2000, Nuclear medicine and biology.

[27]  Kiichi Ishiwata,et al.  In vivo evaluation of [11C]SA4503 as a PET ligand for mapping CNS sigma1 receptors , 2000 .

[28]  R. Mach,et al.  Sigma-2 receptors as a biomarker of proliferation in solid tumours , 2000, British Journal of Cancer.

[29]  G. Pasternak,et al.  Cloning and Characterization of a Mouse σ1 Receptor , 1998 .

[30]  V. Ganapathy,et al.  Cloning and Functional Characterization of a σ Receptor from Rat Brain , 1998 .

[31]  V. Ganapathy,et al.  Cloning and functional expression of the human type 1 sigma receptor (hSigmaR1). , 1996, Biochemical and biophysical research communications.

[32]  M. Kassiou,et al.  Comparison of binding parameters of σ1 and σ2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes , 1996 .

[33]  E. Kempner,et al.  Purification, molecular cloning, and expression of the mammalian sigma1-binding site. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  W. Bowen,et al.  Sigma receptors are expressed in human non-small cell lung carcinoma. , 1995, Life sciences.

[35]  W. Bowen,et al.  Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. , 1995, Cancer research.

[36]  W. Bowen,et al.  Rat liver and kidney contain high densities of σ1 and σ2 receptors: characterization by ligand binding and photoaffinity labeling , 1994 .

[37]  D. DeHaven-Hudkins,et al.  Characterization of the binding of [3H](+)-pentazocine to σ recognition sites in guinea pig brain , 1992 .

[38]  Y. Cheng,et al.  Linear pharmacokinetics of haloperidol in the rat , 1992, Biopharmaceutics & drug disposition.

[39]  M. Dumont,et al.  Interaction of 1,3-di(2-[5-3H]tolyl) guanidine with sigma 2 binding sites in rat heart membrane preparations. , 1991, European journal of pharmacology.

[40]  S. Homan,et al.  Overexpression of σ Receptors in Nonneural Human Tumors , 1991 .

[41]  T. Su,et al.  Sigma receptors. Putative links between nervous, endocrine and immune systems. , 1991, European journal of biochemistry.

[42]  S. Ross.  Heterogeneous binding of sigma radioligands in the rat brain and liver: possible relationship to subforms of cytochrome P-450. , 1991, Pharmacology & toxicology.

[43]  W. Bowen,et al.  Sigma receptors: biology and function. , 1990, Pharmacological reviews.

[44]  W. Bowen,et al.  A sigma-like binding site in rat pheochromocytoma (PC12) cells: decreased affinity for (+)-benzomorphans and lower molecular weight suggest a different sigma receptor form from that of guinea pig brain , 1990, Brain Research.

[45]  T. Su,et al.  Haloperidol-sensitive (+)[3H]SKF-10,047 binding sites (sigma sites) exhibit a unique distribution in rat brain subcellular fractions. , 1990, European journal of pharmacology.

[46]  E. D. De Souza,et al.  Sigma-receptors in endocrine organs: identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. , 1989, Endocrinology.

[47]  E. London,et al.  Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. , 1988, Science.

[48]  S. Mclean,et al.  Autoradiographic visualization of haloperidol-sensitive sigma receptors in guinea-pig brain , 1988, Neuroscience.

[49]  N. Samovilova,et al.  (+)-[3H]SK&F 10,047 sites in rat liver , 1988 .

[50]  J. Thompson,et al.  The effects of morphine- and nalorphine- like drugs in the nondependent and morphine-dependent chronic spinal dog. , 1976, The Journal of pharmacology and experimental therapeutics.

[51]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[52]  Teruo Hayashi,et al.  Sigma-1 receptor chaperones at the ER-mitochondrion interface regulate Ca(2+) signaling and cell survival. , 2007, Cell.

[53]  R. Mach,et al.  Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled sigma2-receptor ligands. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[54]  R. Mach,et al.  Carbon-11 labeled sigma2 receptor ligands for imaging breast cancer. , 2005, Nuclear medicine and biology.

[55]  R. Mach,et al.  Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. , 2004, Bioorganic & medicinal chemistry letters.

[56]  G. Hortobagyi,et al.  Expression of sigma 1 receptor in human breast cancer , 2004, Breast Cancer Research and Treatment.

[57]  K. Ishii,et al.  Tumor imaging with 2 sigma-receptor ligands, 18F-FE-SA5845 and 11C-SA4503: a feasibility study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[58]  M. Senda,et al.  In vivo evaluation of [(11)C]SA4503 as a PET ligand for mapping CNS sigma(1) receptors. , 2000, Nuclear medicine and biology.

[59]  V. Ganapathy,et al.  Cloning and functional characterization of a sigma receptor from rat brain. , 1998, Journal of neurochemistry.

[60]  J. Xu,et al.  Cloning and characterization of a mouse sigma1 receptor. , 1998, Journal of neurochemistry.

[61]  R. Mach,et al.  Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. , 1997, Cancer research.

[62]  M. Kassiou,et al.  Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes. , 1996, European journal of pharmacology.

[63]  W. Bowen,et al.  Rat liver and kidney contain high densities of sigma 1 and sigma 2 receptors: characterization by ligand binding and photoaffinity labeling. , 1994, European journal of pharmacology.

[64]  D. DeHaven-Hudkins,et al.  Allosteric modulation of ligand binding to [3H](+)pentazocine-defined sigma recognition sites by phenytoin. , 1993, Life Science.

[65]  W. Bowen,et al.  A proposal for the classification of sigma binding sites. , 1992, Trends in pharmacological sciences.

[66]  D. DeHaven-Hudkins,et al.  Characterization of the binding of [3H](+)-pentazocine to sigma recognition sites in guinea pig brain. , 1992, European journal of pharmacology.

[67]  S. Homan,et al.  Overexpression of sigma receptors in nonneural human tumors. , 1991, Cancer research.

[68]  J. Musacchio,et al.  SKF 525-A and cytochrome P-450 ligands inhibit with high affinity the binding of [3H]dextromethorphan and sigma ligands to guinea pig brain. , 1991, Life sciences.

[69]  N. Samovilova,et al.  (+)-[3H]SK&F 10,047 binding sites in rat liver. , 1988, European journal of pharmacology.

[70]  R. Hotchkiss,et al.  Molecular Cancer Selective Sigma-2 Ligands Preferentially Bind to Pancreatic Adenocarcinomas: Applications in Diagnostic Imaging and Therapy , 2022 .